Italy's urgent pro-industry talks face patient wait
This article was originally published in Clinica
Despite the urgency voiced by Italy’s austerity-beleaguered medtech industry following the elections (www.clinica.co.uk, 28 February 2013), the sector must wait at least another three weeks for parliamentarians to be anywhere near ready to discuss how best to help the country through its economic crisis, including completing the country’s austerity measures. Formalities around the registration of members of the Chamber of Deputies and the Senate will kick off next week, with the first serious talks between the political groups and alliances that emerge due to take place from 15 March, according to a parliamentary calendar described in national reports. These groupings and their leaders are not expected to be in place before 20 March, and the election of the new prime minister is likely to take place in the last week of March. “The range of possible scenarios is wide open and too hard to predict,” according to healthcare news daily Quotidianosanità.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.